Cargando…

Equine arteritis virus

Equine arteritis virus (EAV) is a small, enveloped, positive-stranded RNA virus, in the family Arteriviridae, W.H.ich can infect both horses and donkeys. While the majority of EAV infections are asymptomatic, acutely infected animals may develop a wide range of clinical signs, including pyrexia, lim...

Descripción completa

Detalles Bibliográficos
Autores principales: Glaser, A.L., Chirnside, E.D., Horzinek, M.C., de Vries, A.A.F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 1997
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127492/
https://www.ncbi.nlm.nih.gov/pubmed/16728076
http://dx.doi.org/10.1016/S0093-691X(97)00107-6
_version_ 1783516372379107328
author Glaser, A.L.
Chirnside, E.D.
Horzinek, M.C.
de Vries, A.A.F.
author_facet Glaser, A.L.
Chirnside, E.D.
Horzinek, M.C.
de Vries, A.A.F.
author_sort Glaser, A.L.
collection PubMed
description Equine arteritis virus (EAV) is a small, enveloped, positive-stranded RNA virus, in the family Arteriviridae, W.H.ich can infect both horses and donkeys. While the majority of EAV infections are asymptomatic, acutely infected animals may develop a wide range of clinical signs, including pyrexia, limb and ventral edema, depression, rhinitis, and conjunctivitis. The virus may cause abortion and has caused mortality in neonates. After natural EAV infection, most horses develop a solid, long-term immunity to the disease. Marzz and geldings eliminate the virus within 60 days, but 30 to 60% of acutely infected stallions will become persistently infected. These persistently infected animals maintain EAV within the reproductive tract, shed virus continuously in the semen, and can transmit the virus venereally. Mares infected venereally may not have clinical signs, but they shed large amounts of virus in nasopharyngeal secretions and in urine, which may result in lateral spread of the infection by an aerosol route. The consequences of venereally acquired infection are minimal, with no known effects on conception rate, but mares infected at a late stages of gestation may abort. Identification of carrier stallions is crucial to control the dissemination of EAV. The stallions can be identified by serological screening using a virus neutralization (VN) test. If positive at a titer of ≥ 1:4, the stallion should be tested for persistent infection by virus isolation from the sperm-rich fraction of the ejaculate, or by test mating Shedding stallions should not be used for breeding, or should be bred only to mares seropositive from a natural infection or from vaccination, the mares should be subsequently isolated from seronegative horses for three weeks after natural or artificial insemination. A live attenuated (ARVAC) and a formalin-inactivated (ARTERVAC) vaccine are available. Both vaccines induce virus-neutralizing antibodies, the presence of which correlates with protection from disease, abortion, and the development of a persistent infection. Serological investigations indicate that EAV has a worldwide distribution and that its prevalence is increasing. As a consequence, an increasing number of equine viral arteritis (EVA) outbreaks is being reported. This trend is likely to continue unless action is taken to slow or halt the transmission of this agent through semen.
format Online
Article
Text
id pubmed-7127492
institution National Center for Biotechnology Information
language English
publishDate 1997
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-71274922020-04-08 Equine arteritis virus Glaser, A.L. Chirnside, E.D. Horzinek, M.C. de Vries, A.A.F. Theriogenology Article Equine arteritis virus (EAV) is a small, enveloped, positive-stranded RNA virus, in the family Arteriviridae, W.H.ich can infect both horses and donkeys. While the majority of EAV infections are asymptomatic, acutely infected animals may develop a wide range of clinical signs, including pyrexia, limb and ventral edema, depression, rhinitis, and conjunctivitis. The virus may cause abortion and has caused mortality in neonates. After natural EAV infection, most horses develop a solid, long-term immunity to the disease. Marzz and geldings eliminate the virus within 60 days, but 30 to 60% of acutely infected stallions will become persistently infected. These persistently infected animals maintain EAV within the reproductive tract, shed virus continuously in the semen, and can transmit the virus venereally. Mares infected venereally may not have clinical signs, but they shed large amounts of virus in nasopharyngeal secretions and in urine, which may result in lateral spread of the infection by an aerosol route. The consequences of venereally acquired infection are minimal, with no known effects on conception rate, but mares infected at a late stages of gestation may abort. Identification of carrier stallions is crucial to control the dissemination of EAV. The stallions can be identified by serological screening using a virus neutralization (VN) test. If positive at a titer of ≥ 1:4, the stallion should be tested for persistent infection by virus isolation from the sperm-rich fraction of the ejaculate, or by test mating Shedding stallions should not be used for breeding, or should be bred only to mares seropositive from a natural infection or from vaccination, the mares should be subsequently isolated from seronegative horses for three weeks after natural or artificial insemination. A live attenuated (ARVAC) and a formalin-inactivated (ARTERVAC) vaccine are available. Both vaccines induce virus-neutralizing antibodies, the presence of which correlates with protection from disease, abortion, and the development of a persistent infection. Serological investigations indicate that EAV has a worldwide distribution and that its prevalence is increasing. As a consequence, an increasing number of equine viral arteritis (EVA) outbreaks is being reported. This trend is likely to continue unless action is taken to slow or halt the transmission of this agent through semen. Published by Elsevier Inc. 1997-04-15 1998-01-05 /pmc/articles/PMC7127492/ /pubmed/16728076 http://dx.doi.org/10.1016/S0093-691X(97)00107-6 Text en Copyright © 1997 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Glaser, A.L.
Chirnside, E.D.
Horzinek, M.C.
de Vries, A.A.F.
Equine arteritis virus
title Equine arteritis virus
title_full Equine arteritis virus
title_fullStr Equine arteritis virus
title_full_unstemmed Equine arteritis virus
title_short Equine arteritis virus
title_sort equine arteritis virus
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127492/
https://www.ncbi.nlm.nih.gov/pubmed/16728076
http://dx.doi.org/10.1016/S0093-691X(97)00107-6
work_keys_str_mv AT glaseral equinearteritisvirus
AT chirnsideed equinearteritisvirus
AT horzinekmc equinearteritisvirus
AT devriesaaf equinearteritisvirus